Science 9 August 1985: Vol. 229. no. 4713, pp. 563 - 566 DOI: 10.1126/science.2992081

Prev | Table of Contents | Next

Articles

Probing HIV-1 Membrane Liquid Order by Laurdan Staining Reveals Producer Cell-dependent Differences.

M. Lorizate, B. Brugger, H. Akiyama, B. Glass, B. Muller, G. Anderluh, F. T. Wieland, and H.-G. Krausslich (2009)
J. Biol. Chem. 284, 22238-22247
 |  Abstract »  |  Full Text »  |  PDF »

HTLV-1 Tax Is a Critical Lipid Raft Modulator That Hijacks I{kappa}B Kinases to the Microdomains for Persistent Activation of NF-{kappa}B.

J. Huang, T. Ren, H. Guan, Y. Jiang, and H. Cheng (2009)
J. Biol. Chem. 284, 6208-6217
 |  Abstract »  |  Full Text »  |  PDF »

The Naphthyridinone GSK364735 Is a Novel, Potent Human Immunodeficiency Virus Type 1 Integrase Inhibitor and Antiretroviral.

E. P. Garvey, B. A. Johns, M. J. Gartland, S. A. Foster, W. H. Miller, R. G. Ferris, R. J. Hazen, M. R. Underwood, E. E. Boros, J. B. Thompson, et al. (2008)
Antimicrob. Agents Chemother. 52, 901-908
 |  Abstract »  |  Full Text »  |  PDF »

Modulation of Human Immunodeficiency Virus Type 1 Infectivity through Incorporation of Tetraspanin Proteins.

K. Sato, J. Aoki, N. Misawa, E. Daikoku, K. Sano, Y. Tanaka, and Y. Koyanagi (2008)
J. Virol. 82, 1021-1033
 |  Abstract »  |  Full Text »  |  PDF »

Human Immunodeficiency Virus Type 1 Derivative with 7% Simian Immunodeficiency Virus Genetic Content Is Able To Establish Infections in Pig-Tailed Macaques.

T. Igarashi, R. Iyengar, R. A. Byrum, A. Buckler-White, R. L. Dewar, C. E. Buckler, H. C. Lane, K. Kamada, A. Adachi, and M. A. Martin (2007)
J. Virol. 81, 11549-11552
 |  Abstract »  |  Full Text »  |  PDF »

Although Macrophage-Tropic Simian/Human Immunodeficiency Viruses Can Exhibit a Range of Pathogenic Phenotypes, a Majority of Isolates Induce No Clinical Disease in Immunocompetent Macaques.

T. Igarashi, O. K. Donau, H. Imamichi, Y. Nishimura, T. S. Theodore, R. Iyengar, C. Erb, A. Buckler-White, C. E. Buckler, and M. A. Martin (2007)
J. Virol. 81, 10669-10679
 |  Abstract »  |  Full Text »  |  PDF »

Development of a New Methodology for Screening of Human Immunodeficiency Virus Type 1 Microbicides Based on Real-Time PCR Quantification.

R. S. Aguiar, L. J. Costa, H. S. Pereira, R. M. Brindeiro, and A. Tanuri (2007)
Antimicrob. Agents Chemother. 51, 638-644
 |  Abstract »  |  Full Text »  |  PDF »

Effective Suppression of Human Immunodeficiency Virus Type 1 through a Combination of Short- or Long-Hairpin RNAs Targeting Essential Sequences for Retroviral Integration..

H. Nishitsuji, M. Kohara, M. Kannagi, and T. Masuda (2006)
J. Virol. 80, 7658-7666
 |  Abstract »  |  Full Text »  |  PDF »

Functional Correlation between a Novel Amino Acid Insertion at Codon 19 in the Protease of Human Immunodeficiency Virus Type 1 and Polymorphism in the p1/p6 Gag Cleavage Site in Drug Resistance and Replication Fitness..

T. W. Brann, R. L. Dewar, M.-K. Jiang, A. Shah, K. Nagashima, J. A. Metcalf, J. Falloon, H. C. Lane, and T. Imamichi (2006)
J. Virol. 80, 6136-6145
 |  Abstract »  |  Full Text »  |  PDF »

The HIV lipidome: A raft with an unusual composition.

B. Brugger, B. Glass, P. Haberkant, I. Leibrecht, F. T. Wieland, and H.-G. Krausslich (2006)
PNAS 103, 2641-2646
 |  Abstract »  |  Full Text »  |  PDF »

Oxadiazols: a New Class of Rationally Designed Anti-Human Immunodeficiency Virus Compounds Targeting the Nuclear Localization Signal of the Viral Matrix Protein.

O. Haffar, L. Dubrovsky, R. Lowe, R. Berro, F. Kashanchi, J. Godden, C. Vanpouille, J. Bajorath, and M. Bukrinsky (2005)
J. Virol. 79, 13028-13036
 |  Abstract »  |  Full Text »  |  PDF »

Mutations That Abrogate Human Immunodeficiency Virus Type 1 Reverse Transcriptase Dimerization Affect Maturation of the Reverse Transcriptase Heterodimer.

J. Wapling, K. L. Moore, S. Sonza, J. Mak, and G. Tachedjian (2005)
J. Virol. 79, 10247-10257
 |  Abstract »  |  Full Text »  |  PDF »

Few Mutations in the 5' Leader Region Mediate Fitness Recovery of Debilitated Human Immunodeficiency Type 1 Viruses.

E. Yuste, A. V. Borderia, E. Domingo, and C. Lopez-Galindez (2005)
J. Virol. 79, 5421-5427
 |  Abstract »  |  Full Text »  |  PDF »

Inhibition of Human Immunodeficiency Virus Replication by a Dual CCR5/CXCR4 Antagonist.

K. Princen, S. Hatse, K. Vermeire, S. Aquaro, E. De Clercq, L.-O. Gerlach, M. Rosenkilde, T. W. Schwartz, R. Skerlj, G. Bridger, et al. (2004)
J. Virol. 78, 12996-13006
 |  Abstract »  |  Full Text »  |  PDF »

Beyond Help: Direct Effector Functions of Human Immunodeficiency Virus Type 1-Specific CD4+ T Cells.

P. J. Norris, H. F. Moffett, O. O. Yang, D. E. Kaufmann, M. J. Clark, M. M. Addo, and E. S. Rosenberg (2004)
J. Virol. 78, 8844-8851
 |  Abstract »  |  Full Text »  |  PDF »

Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: Implications for HIV-1 vaccine development.

Y. Nishimura, T. Igarashi, N. L. Haigwood, R. Sadjadpour, O. K. Donau, C. Buckler, R. J. Plishka, A. Buckler-White, and M. A. Martin (2003)
PNAS 100, 15131-15136
 |  Abstract »  |  Full Text »  |  PDF »

Transcriptional activation of immediate-early gene ETR101 by human T-cell leukaemia virus type I Tax.

L. Chen, S. Ma, B. Li, T. Fink, V. Zachar, M. Takahashi, J. Cuttichia, L.-C. Tsui, P. Ebbesen, and X. Liu (2003)
J. Gen. Virol. 84, 3203-3214
 |  Abstract »  |  Full Text »  |  PDF »

Actinomycin D Induces High-Level Resistance to Thymidine Analogs in Replication of Human Immunodeficiency Virus Type 1 by Interfering with Host Cell Thymidine Kinase Expression.

T. Imamichi, M. A. Murphy, J. W. Adelsberger, J. Yang, C. M. Watkins, S. C. Berg, M. W. Baseler, R. A. Lempicki, J. Guo, J. G. Levin, et al. (2003)
J. Virol. 77, 1011-1020
 |  Abstract »  |  Full Text »  |  PDF »

Control of Viremia and Prevention of Simian-Human Immunodeficiency Virus-Induced Disease in Rhesus Macaques Immunized with Recombinant Vaccinia Viruses plus Inactivated Simian Immunodeficiency Virus and Human Immunodeficiency Virus Type 1 Particles.

R. L. Willey, R. Byrum, M. Piatak, Y. B. Kim, M. W. Cho, J. L. Rossio Jr., J. Bess Jr., T. Igarashi, Y. Endo, L. O. Arthur, et al. (2003)
J. Virol. 77, 1163-1174
 |  Abstract »  |  Full Text »  |  PDF »

Determination of a Statistically Valid Neutralization Titer in Plasma That Confers Protection against Simian-Human Immunodeficiency Virus Challenge following Passive Transfer of High-Titered Neutralizing Antibodies.

Y. Nishimura, T. Igarashi, N. Haigwood, R. Sadjadpour, R. J. Plishka, A. Buckler-White, R. Shibata, and M. A. Martin (2002)
J. Virol. 76, 2123-2130
 |  Abstract »  |  Full Text »  |  PDF »

Regional Clustering of Shared Neutralization Determinants on Primary Isolates of Clade C Human Immunodeficiency Virus Type 1 from South Africa.

R. Bures, L. Morris, C. Williamson, G. Ramjee, M. Deers, S. A. Fiscus, S. Abdool-Karim, and D. C. Montefiori (2002)
J. Virol. 76, 2233-2244
 |  Abstract »  |  Full Text »  |  PDF »

Frequency-dependent selection in human immunodeficiency virus type 1.

E. Yuste, A. Moya, and C. Lopez-Galindez (2002)
J. Gen. Virol. 83, 103-106
 |  Abstract »  |  Full Text »  |  PDF »

Correlation between Viral Resistance to Zidovudine and Resistance at the Reverse Transcriptase Level for a Panel of Human Immunodeficiency Virus Type 1 Mutants.

J. Lennerstrand, K. Hertogs, D. K. Stammers, and B. A. Larder (2001)
J. Virol. 75, 7202-7205
 |  Abstract »  |  Full Text »  |  PDF »

Biochemical Mechanism of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Resistance to Stavudine.

J. Lennerstrand, D. K. Stammers, and B. A. Larder (2001)
Antimicrob. Agents Chemother. 45, 2144-2146
 |  Abstract »  |  Full Text »  |  PDF »

Induction of Neutralizing Antibodies and Gag-Specific Cellular Immune Responses to an R5 Primary Isolate of Human Immunodeficiency Virus Type 1 in Rhesus Macaques.

D. C. Montefiori, J. T. Safrit, S. L. Lydy, A. P. Barry, M. Bilska, H. T. T. Vo, M. Klein, J. Tartaglia, H. L. Robinson, and B. Rovinski (2001)
J. Virol. 75, 5879-5890
 |  Abstract »  |  Full Text »  |  PDF »

Cell-to-Cell Contact Results in a Selective Translocation of Maternal Human Immunodeficiency Virus Type 1 Quasispecies across a Trophoblastic Barrier by both Transcytosis and Infection.

S. Lagaye, M. Derrien, E. Menu, C. Coito, E. Tresoldi, P. Mauclere, G. Scarlatti, G. Chaouat, F. Barre-Sinoussi, M. Bomsel, et al. (2001)
J. Virol. 75, 4780-4791
 |  Abstract »  |  Full Text »  |  PDF »

Vaccine-Elicited V3 Loop-Specific Antibodies in Rhesus Monkeys and Control of a Simian-Human Immunodeficiency Virus Expressing a Primary Patient Human Immunodeficiency Virus Type 1 Isolate Envelope.

N. L. Letvin, S. Robinson, D. Rohne, M. K. Axthelm, J. W. Fanton, M. Bilska, T. J. Palker, H.-X. Liao, B. F. Haynes, and D. C. Montefiori (2001)
J. Virol. 75, 4165-4175
 |  Abstract »  |  Full Text »  |  PDF »

Amino Acid Deletion at Codon 67 and Thr-to-Gly Change at Codon 69 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Novel Drug Resistance Profiles.

T. Imamichi, M. A. Murphy, H. Imamichi, and H. C. Lane (2001)
J. Virol. 75, 3988-3992
 |  Abstract »  |  Full Text »  |  PDF »

Relative Replication Fitness of a High-Level 3'-Azido-3'-Deoxythymidine-Resistant Variant of Human Immunodeficiency Virus Type 1 Possessing an Amino Acid Deletion at Codon 67 and a Novel Substitution (Thrright-arrowGly) at Codon 69.

T. Imamichi, S. C. Berg, H. Imamichi, J. C. Lopez, J. A. Metcalf, J. Falloon, and H. C. Lane (2000)
J. Virol. 74, 10958-10964
 |  Abstract »  |  Full Text »  |  PDF »

Nitric Oxide Synthesis Enhances Human Immunodeficiency Virus Replication in Primary Human Macrophages.

D. Blond, H. Raoul, R. Le Grand, and D. Dormont (2000)
J. Virol. 74, 8904-8912
 |  Abstract »  |  Full Text »  |  PDF »

Viral Entry as the Primary Target for the Anti-HIV Activity of Chicoric Acid and Its Tetra-Acetyl Esters.

W. Pluymers, N. Neamati, C. Pannecouque, V. Fikkert, C. Marchand, T. R. Burke Jr., Y. Pommier, D. Schols, E. De Clercq, Z. Debyser, et al. (2000)
Mol. Pharmacol. 58, 641-648
 |  Abstract »  |  Full Text »

Biochemical and Structural Analysis of Isolated Mature Cores of Human Immunodeficiency Virus Type 1.

R. Welker, H. Hohenberg, U. Tessmer, C. Huckhagel, and H.-G. Krausslich (2000)
J. Virol. 74, 1168-1177
 |  Abstract »  |  Full Text »  |  PDF »

High-Level Resistance to 3'-Azido-3'-Deoxythimidine due to a Deletion in the Reverse Transcriptase Gene of Human Immunodeficiency Virus Type 1.

T. Imamichi, T. Sinha, H. Imamichi, Y.-M. Zhang, J. A. Metcalf, J. Falloon, and H. C. Lane (2000)
J. Virol. 74, 1023-1028
 |  Abstract »  |  Full Text »  |  PDF »

Transcriptional activation of human TR3/nur77 gene expression by human T-lymphotropic virus type I Tax protein through two AP-1-like elements.

X. Liu, X. Chen, V. Zachar, C. Chang, and P. Ebbesen (1999)
J. Gen. Virol. 80, 3073-3081
 |  Abstract »  |  Full Text »

Characterization of Primary Isolate-Like Variants of Simian-Human Immunodeficiency Virus.

J. M. Crawford, P. L. Earl, B. Moss, K. A. Reimann, M. S. Wyand, K. H. Manson, M. Bilska, J. T. Zhou, C. D. Pauza, P. W. H. I. Parren, et al. (1999)
J. Virol. 73, 10199-10207
 |  Abstract »  |  Full Text »  |  PDF »

Human Immunodeficiency Virus Type 1 Cloning Vectors for Antiretroviral Resistance Testing.

J. Martinez-Picado, L. Sutton, M. P. De Pasquale, A. V. Savara, and R. T. D'Aquila (1999)
J. Clin. Microbiol. 37, 2943-2951
 |  Abstract »  |  Full Text »  |  PDF »

A Family of Insertion Mutations between Codons 67 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Multinucleoside Analog Resistance.

B. A. Larder, S. Bloor, S. D. Kemp, K. Hertogs, R. L. Desmet, V. Miller, M. Sturmer, S. Staszewski, J. Ren, D. K. Stammers, et al. (1999)
Antimicrob. Agents Chemother. 43, 1961-1967
 |  Abstract »  |  Full Text »  |  PDF »

Second-Site Reversion of a Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutant That Restores Enzyme Function and Replication Capacity.

I. Olivares, V. Sanchez-Merino, M. A. Martinez, E. Domingo, C. Lopez-Galindez, and L. Menendez-Arias (1999)
J. Virol. 73, 6293-6298
 |  Abstract »  |  Full Text »  |  PDF »

Infection of HIV-1 Transgenic Mice with Mycobacterium avium Induces the Expression of Infectious Virus Selectively from a Mac-1-Positive Host Cell Population.

T. M. Doherty, C. Chougnet, M. Schito, B. K. Patterson, C. Fox, G. M. Shearer, G. Englund, and A. Sher (1999)
J. Immunol. 163, 1506-1515
 |  Abstract »  |  Full Text »  |  PDF »

Defective DNA Repair in Cells With Human T-Cell Leukemia/Bovine Leukemia Viruses: Role of tax Gene.

S. M. Philpott and G. C. Buehring (1999)
J Natl Cancer Inst 91, 933-942
 |  Abstract »  |  Full Text »  |  PDF »

Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1.

J. Martinez-Picado, A. V. Savara, L. Sutton, and R. T. D'Aquila (1999)
J. Virol. 73, 3744-3752
 |  Abstract »  |  Full Text »  |  PDF »

Drastic Fitness Loss in Human Immunodeficiency Virus Type 1 upon Serial Bottleneck Events.

E. Yuste, S. Sanchez-Palomino, C. Casado, E. Domingo, and C. Lopez-Galindez (1999)
J. Virol. 73, 2745-2751
 |  Abstract »  |  Full Text »  |  PDF »

Activity of Different Bicyclam Derivatives against Human Immunodeficiency Virus Depends on Their Interaction with the CXCR4 Chemokine Receptor.

J. A. Esté, C. Cabrera, E. De Clercq, S. Struyf, J. Van Damme, G. Bridger, R. T. Skerlj, M. J. Abrams, G. Henson, A. Gutierrez, et al. (1999)
Mol. Pharmacol. 55, 67-73
 |  Abstract »  |  Full Text »

Coresistance to Zidovudine and Foscarnet Is Associated with Multiple Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase.

G. Tachedjian, M. French, and J. Mills (1998)
Antimicrob. Agents Chemother. 42, 3038-3043
 |  Abstract »  |  Full Text »  |  PDF »

Prostaglandin E2 Up-regulates HIV-1 Long Terminal Repeat-driven Gene Activity in T Cells via NF-kappa B-dependent and -Independent Signaling Pathways.

N. Dumais, B. Barbeau, M. Olivier, and M. J. Tremblay (1998)
J. Biol. Chem. 273, 27306-27314
 |  Abstract »  |  Full Text »  |  PDF »

Differential Expression of Nur77 Family Members in Human T-Lymphotropic Virus Type 1-Infected Cells: Transactivation of the TR3/nur77 Gene by Tax Protein.

X. Chen, V. Zachar, C. Chang, P. Ebbesen, and X. Liu (1998)
J. Virol. 72, 6902-6906
 |  Abstract »  |  Full Text »  |  PDF »

S-1153 Inhibits Replication of Known Drug-Resistant Strains of Human Immunodeficiency Virus Type 1.

T. Fujiwara, A. Sato, M. El-Farrash, S. Miki, K. Abe, Y. Isaka, M. Kodama, Y. Wu, L. B. Chen, H. Harada, et al. (1998)
Antimicrob. Agents Chemother. 42, 1340-1345
 |  Abstract »  |  Full Text »  |  PDF »

A Novel Polymorphism at Codon 333 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Can Facilitate Dual Resistance to Zidovudine and L-2',3'-Dideoxy-3'-Thiacytidine.

S. D. Kemp, C. Shi, S. Bloor, P. R. Harrigan, J. W. Mellors, and B. A. Larder (1998)
J. Virol. 72, 5093-5098
 |  Abstract »  |  Full Text »  |  PDF »

Factors Secreted by Human T Lymphotropic Virus Type I (HTLV-I)-infected Cells Can Enhance or Inhibit Replication of HIV-1 in HTLV-I-uninfected Cells: Implications for In Vivo Coinfection with HTLV-I and HIV-1.

H. Moriuchi, M. Moriuchi, and A. S. Fauci (1998)
J. Exp. Med. 187, 1689-1697
 |  Abstract »  |  Full Text »  |  PDF »

T-Cell-Line-Tropic Human Immunodeficiency Virus Type 1 That Is Made Resistant to Stromal Cell-Derived Factor 1alpha Contains Mutations in the Envelope gp120 but Does Not Show a Switch in Coreceptor Use.

D. Schols, J. A. Este, C. Cabrera, and E. De Clercq (1998)
J. Virol. 72, 4032-4037
 |  Abstract »  |  Full Text »  |  PDF »

The Putative Alpha Helix 2 of Human Immunodeficiency Virus Type 1 Vpr Contains a Determinant Which Is Responsible for the Nuclear Translocation of Proviral DNA in Growth-Arrested Cells.

Z. Nie, D. Bergeron, R. A. Subbramanian, X.-J. Yao, F. Checroune, N. Rougeau, and E. A. Cohen (1998)
J. Virol. 72, 4104-4115
 |  Abstract »  |  Full Text »  |  PDF »

Sequential Steps in Human Immunodeficiency Virus Particle Maturation Revealed by Alterations of Individual Gag Polyprotein Cleavage Sites.

K. Wiegers, G. Rutter, H. Kottler, U. Tessmer, H. Hohenberg, and H.-G. Krausslich (1998)
J. Virol. 72, 2846-2854
 |  Abstract »  |  Full Text »  |  PDF »

Cleavage of Human Immunodeficiency Virus Type 1 Proteinase from the N-Terminally Adjacent p6* Protein Is Essential for Efficient Gag Polyprotein Processing and Viral Infectivity.

U. Tessmer and H.-G. Krausslich (1998)
J. Virol. 72, 3459-3463
 |  Abstract »  |  Full Text »  |  PDF »

The Lipophosphoglycan of Leishmania donovani Up-Regulates HIV-1 Transcription in T Cells Through the Nuclear Factor-{kappa}B Elements.

R. Bernier, B. Barbeau, M. J. Tremblay, and M. Olivier (1998)
J. Immunol. 160, 2881-2888
 |  Abstract »  |  Full Text »  |  PDF »

Evidence that Antibody-Mediated Neutralization of Human Immunodeficiency Virus Type 1 by Sera from Infected Individuals Is Independent of Coreceptor Usage.

D. C. Montefiori, R. G. Collman, T. R. Fouts, J. Y. Zhou, M. Bilska, J. A. Hoxie, J. P. Moore, and D. P. Bolognesi (1998)
J. Virol. 72, 1886-1893
 |  Abstract »  |  Full Text »  |  PDF »

Amino Acid Analogs Activate NF-kappa B through Redox-dependent Ikappa B-alpha Degradation by the Proteasome without Apparent Ikappa B-alpha Phosphorylation. CONSEQUENCE ON HIV-1 LONG TERMINAL REPEAT ACTIVATION.

C. Kretz-Remy, E. E. M. Bates, and A.-P. Arrigo (1998)
J. Biol. Chem. 273, 3180-3191
 |  Abstract »  |  Full Text »  |  PDF »

Inhibition of p53 Transactivation Function by the Human T-Cell Lymphotropic Virus Type 1 Tax Protein.

C. A. Pise-Masison, K.-S. Choi, M. Radonovich, J. Dittmer, S.-J. Kim, and J. N. Brady (1998)
J. Virol. 72, 1165-1170
 |  Abstract »  |  Full Text »  |  PDF »

Human Immunodeficiency Virus Glycoprotein gp120 as the Primary Target for the Antiviral Action of AR177 (Zintevir).

J. A. Esté, C. Cabrera, D. Schols, P. Cherepanov, A. Gutierrez, M. Witvrouw, C. Pannecouque, Z. Debyser, R. F. Rando, B. Clotet, et al. (1998)
Mol. Pharmacol. 53, 340-345
 |  Abstract »  |  Full Text »

The Acquisition of Host-Derived Major Histocompatibility Complex Class II Glycoproteins by Human Immunodeficiency Virus Type 1 Accelerates the Process of Virus Entry and Infection in Human T-Lymphoid Cells.

R. Cantin, J.-F. Fortin, G. Lamontagne, and M. Tremblay (1997)
Blood 90, 1091-1100
 |  Abstract »  |  Full Text »  |  PDF »

CXCR4/fusin Is Not a Species-specific Barrier in Murine Cells for HIV-1 Entry.

K. Tachibana, T. Nakajima, A. Sato, K. Igarashi, H. Shida, H. Iizasa, N. Yoshida, O. Yoshie, T. Kishimoto, and T. Nagasawa (1997)
J. Exp. Med. 185, 1865-1870
 |  Abstract »  |  Full Text »  |  PDF »

UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-Acetylgalactosaminyltransferase.

T. Sørensen, T. White, H. H. Wandall, A. K. Kristensen, P. Roepstorff, and H. Clausen (1995)
J. Biol. Chem. 270, 24166-24173
 |  Abstract »  |  Full Text »  |  PDF »

An internally controlled virion PCR for the measurement of HIV-1 RNA in plasma..

V Natarajan, R J Plishka, E W Scott, H C Lane, and N P Salzman (1994)
Genome Res. 3, 346-350
 |  Abstract »  |  PDF »

A Patient With Progressive Myelopathy and Antibodies to Human T-Cell Leukemia Virus Type I and Human Immunodeficiency Virus Type 1 in Serum and Cerebrospinal Fluid.

D. M. Aboulafia, E. H. Saxton, H. Koga, A. Diagne, and J. D. Rosenblatt (1990)
Arch Neurol 47, 477-479
 |  Abstract »  |  PDF »

Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

B. Larder and S. Kemp (1989)
Science 246, 1155-1158
 |  Abstract »  |  PDF »

Human T-Cell Lymphotropic Virus Type I (HTLV-I)-Associated Adult T-Cell Leukemia-Lymphoma in a Patient Infected with Human Immunodeficiency Virus Type 1 (HIV-1).

D. Shibata, R. K. Brynes, A. Rabinowitz, C. A. Hanson, M. L. Slovak, T. J. Spira, and P. Gill (1989)
Ann Intern Med 111, 871-875
 |  Abstract »  |  PDF »

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

B. Larder, G Darby, and D. Richman (1989)
Science 243, 1731-1734
 |  Abstract »  |  PDF »

Type-restricted neutralization of molecular clones of human immunodeficiency virus.

D. Looney, A. Fisher, S. Putney, Rusche JR, R. Redfield, D. Burke, R. Gallo, and F Wong-Staal (1988)
Science 241, 357-359
 |  Abstract »  |  PDF »

Biologic features of HIV-1 that correlate with virulence in the host.

C Cheng-Mayer, D Seto, M Tateno, and J. Levy (1988)
Science 240, 80-82
 |  Abstract »  |  PDF »

A quantitative bioassay for HIV-1 based on trans-activation.

B. Felber and G. Pavlakis (1988)
Science 239, 184-187
 |  Abstract »  |  PDF »

Transmission of HTLV-I and HIV Among Homosexual Men in Trinidad.

C. Bartholomew, W. C. Saxinger, J. W. Clark, M. Gail, A. Dudgeon, B. Mahabir, B. Hull-Drysdale, F. Cleghorn, R. C. Gallo, and W. A. Blattner (1987)
JAMA 257, 2604-2608
 |  Abstract »  |  PDF »

Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms.

Y Koyanagi, S Miles, R. Mitsuyasu, J. Merrill, H. Vinters, and I. Chen (1987)
Science 236, 819-822
 |  Abstract »  |  PDF »

Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions.

J Sodroski, W. Goh, C Rosen, A Tartar, D Portetelle, A Burny, and W Haseltine (1986)
Science 231, 1549-1553
 |  Abstract »  |  PDF »

Directing the Immune Response to Carbohydrate Antigens.

G. Cunto-Amesty, T. K. Dam, P. Luo, B. Monzavi-Karbassi, C. F. Brewer, T. C. Van Cott, and T. Kieber-Emmons (2001)
J. Biol. Chem. 276, 30490-30498
 |  Abstract »  |  Full Text »  |  PDF »

To Advertise   |   Find Products